Dr. Christian Behrenbruch is a Bioscience Entrepreneur & CEO of Telx Pharmaceuticals Limited, a clinical-stage biotechnology company dedicated to developing a pipeline of advanced "theranostic", diagnostic and therapeutic, assets for a number of unmet needs in cancer care.

Behrenbruch has twenty years of healthcare entrepreneurship and executive leadership experience. He has previously served in a CEO or Executive Director capacity at Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc.

As well, he a formerly served as Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix) and was the former Chairman of Cell Therapies P/L.

He is a director of Factor Therapeutics and Amplia Therapeutics P/L, a Chairman of the Monash Engineering and IT Foundation Board, and is an Adjunct Professor at Monash University.

Behrenbruch holds a Ph.D. in biomedical engineering from the University of Oxford, an executive MBA jointly awarded from New York University, HEC Paris and the London School of Economics and a Juris Doctor from the University of Melbourne.

Medicine Pharmaceutical, Technology, Science, Science and Technology Professionals, CEO, Chief Executive Officer (CEO), Professors, Law, Lawyers, Entrepreneurship,